Molecular Imaging

Molecular imaging (also called nuclear medicine or nuclear imaging) can image the function of cells inside the body at the molecular level. This includes the imaging modalities of positron emission computed tomography (PET) and single photon emission computed tomography (SPECT) imaging. How does PET and SPECT imaging work? Small amounts of radioactive material (radiopharmaceuticals) injected into a patient. These can use sugars or chemical traits to bond to specific cells. The radioactive material is taken up by cells that consume the sugars. The radiation emitted from inside the body is detected by photon detectors outside the body. Computers take the data to assemble images of the radiation emissions. Nuclear images may appear fuzzy or ghostly rather than the sharper resolution from MRI and CT.  But, it provides metabolic information at a cellular level, showing if there are defects in the function of the heart, areas of very high metabolic activity associated with cancer cells, or areas of inflammation, data not available from other modalities. These noninvasive imaging exams are used to diagnose cancer, heart disease, Alzheimer’s and Parkinson’s disease, bone disorders and other disorders. 

ASNC now taking abstracts for 2014 scientific session

The American Society of Nuclear Cardiology (ASNC) announced Feb. 27 that abstract submissions are now being taken for the upcoming ASNC 2014 meeting scheduled for Sept. 18-21 at the Seaport World Trade Center in Boston.

SPECT tracks colorectal tumor-sniping chemoradiotherapy

A treatment strategy for colon cancer combining molecular imaging, a radioimmunotherapy that seeks colon-specific anatomy and concomitant chemotherapy is being bundled as chemoradiotherapy to take out more metastatic disease, according to a study published online Feb. 20 in the Journal of Nuclear Medicine.

PET parameter is better than a visual read for Hodgkin's lymphoma

A reduction of the FDG maximum standardized uptake value is superior to visual analysis for the evaluation of treatment response in patients with Hodgkin's lymphoma, according to a study published online Feb. 24 in the Journal of Nuclear Medicine.

New chairman of the board for Varian

Varian Medical Systems out of Palo Alto, Calif., elected Andrew Eckert, 52, as head of the board of directors, the manufacturer of radiation oncology technology announced Feb. 20.

Parkinson’s research opens up for patients with genetic mutations

Patients who carry telltale genetic mutations are being targeted for expanded Parkinson’s research in a major study called the Parkinson’s Progression Markers Initiative, led by The Michael J. Fox Foundation, the advocacy group announced Feb. 25.

Endocyte presents new biomarkers and fourth quarter loss

West Lafayette, Ind.-based biopharmaceutical company Endocyte announced Feb. 24 that the company's folate-receptor biomarkers vintafolide and etarfolatide had orphan drug status and were moving closer to approval with a review by the European Committee for Medicinal Products for Human Use (CHMP).

Thumbnail

NeuraCeq gets European approval for amyloid PET imaging

Piramal Imaging announced today that F-18 florbetaben, also known as NeuraCeq, is cleared for commercial marketing by the European Commission.

WMIC 2014 in Seoul is seeking abstracts

Not for another several months, the 2014 World Molecular Imaging Congress (WMIC) is scheduled to take Seoul, Korea, by storm from Sept. 17-20, but this week the Scientific Program Committee has made a formal request for abstracts to be submitted for presentation.